14 results on '"Monagle, Paul"'
Search Results
2. Factors XI and XII in extracorporeal membrane oxygenation:longitudinal profile in children
- Author
-
Drop, Joppe, Letunica, Natasha, Van Den Helm, Suelyn, Heleen van Ommen, C., Wildschut, Enno, de Hoog, Matthijs, van Rosmalen, Joost, Barton, Rebecca, Yaw, Hui Ping, Newall, Fiona, Horton, Stephen B., Chiletti, Roberto, Johansen, Amy, Best, Derek, McKittrick, Joanne, Butt, Warwick, d'Udekem, Yves, MacLaren, Graeme, Linden, Matthew D., Ignjatovic, Vera, Attard, Chantal, Monagle, Paul, Drop, Joppe, Letunica, Natasha, Van Den Helm, Suelyn, Heleen van Ommen, C., Wildschut, Enno, de Hoog, Matthijs, van Rosmalen, Joost, Barton, Rebecca, Yaw, Hui Ping, Newall, Fiona, Horton, Stephen B., Chiletti, Roberto, Johansen, Amy, Best, Derek, McKittrick, Joanne, Butt, Warwick, d'Udekem, Yves, MacLaren, Graeme, Linden, Matthew D., Ignjatovic, Vera, Attard, Chantal, and Monagle, Paul
- Abstract
Background: Extracorporeal membrane oxygenation (ECMO) is used in children with cardiopulmonary failure. While the majority of ECMO centers use unfractionated heparin, other anticoagulants, including factor XI and factor XII inhibitors are emerging, which may prove suitable for ECMO patients. However, before these anticoagulants can be applied in these patients, baseline data of FXI and FXII changes need to be acquired. Objectives: This study aimed to describe the longitudinal profile of FXI and FXII antigenic levels and function before, during, and after ECMO in children. Methods: This is a prospective observational study in neonatal and pediatric patients with ECMO (<18 years). All patients with venoarterial ECMO and with sufficient plasma volume collected before ECMO, on day 1 and day 3, and 24 hours postdecannulation were included. Antigenic levels and functional activity of FXI and FXII were determined in these samples. Longitudinal profiles of these values were created using a linear mixed model. Results: Sixteen patients were included in this study. Mean FXI and FXII antigenic levels (U/mL) changed from 7.9 and 53.2 before ECMO to 6.0 and 34.5 on day 3 and they recovered to 8.8 and 39.4, respectively, after stopping ECMO. Function (%) of FXI and FXII decreased from 59.1 and 59.0 to 49.0 and 50.7 on day 3 and recovered to 66.0 and 54.4, respectively. Conclusion: This study provides the first insights into changes of the contact pathway in children undergoing ECMO. FXI and FXII antigen and function change during ECMO. Results from this study can be used as starting point for future contact pathway anticoagulant studies in pediatric patients with ECMO.
- Published
- 2023
3. Pediatric Organ Dysfunction Information Update Mandate (PODIUM) Contemporary Organ Dysfunction Criteria: Executive Summary.
- Author
-
Bembea, Melania, Bembea, Melania, Agus, Michael, Akcan-Arikan, Ayse, Alexander, Peta, Basu, Rajit, Bennett, Tellen, Bohn, Desmond, Brandão, Leonardo, Brown, Ann-Marie, Carcillo, Joseph, Checchia, Paul, Cholette, Jill, Cheifetz, Ira, Cornell, Timothy, Doctor, Allan, Eckerle, Michelle, Erickson, Simon, Farris, Reid, Faustino, E, Fitzgerald, Julie, Fuhrman, Dana, Giuliano, John, Guilliams, Kristin, Gaies, Michael, Gorga, Stephen, Hall, Mark, Hanson, Sheila, Hartman, Mary, Hassinger, Amanda, Irving, Sharon, Jeffries, Howard, Jouvet, Philippe, Kannan, Sujatha, Karam, Oliver, Khemani, Robinder, Kissoon, Niranjan, Lacroix, Jacques, Laussen, Peter, Leclerc, Francis, Lee, Jan, Leteurtre, Stephane, Lobner, Katie, McKiernan, Patrick, Menon, Kusum, Monagle, Paul, Muszynski, Jennifer, Odetola, Folafoluwa, Parker, Robert, Pathan, Nazima, Pierce, Richard, Pineda, Jose, Prince, Jose, Robinson, Karen, Rowan, Courtney, Ryerson, Lindsay, Sanchez-Pinto, L, Schlapbach, Luregn, Selewski, David, Shekerdemian, Lara, Simon, Dennis, Smith, Lincoln, Squires, James, Squires, Robert, Sutherland, Scott, Ouellette, Yves, Spaeder, Michael, Srinivasan, Vijay, Steiner, Marie, Tasker, Robert, Thiagarajan, Ravi, Thomas, Neal, Tissieres, Pierre, Traube, Chani, Tucci, Marisa, Typpo, Katri, Wainwright, Mark, Ward, Shan, Watson, R, Weiss, Scott, Whitney, Jane, Willson, Doug, Wynn, James, Yehya, Nadir, Zimmerman, Jerry, Bembea, Melania, Bembea, Melania, Agus, Michael, Akcan-Arikan, Ayse, Alexander, Peta, Basu, Rajit, Bennett, Tellen, Bohn, Desmond, Brandão, Leonardo, Brown, Ann-Marie, Carcillo, Joseph, Checchia, Paul, Cholette, Jill, Cheifetz, Ira, Cornell, Timothy, Doctor, Allan, Eckerle, Michelle, Erickson, Simon, Farris, Reid, Faustino, E, Fitzgerald, Julie, Fuhrman, Dana, Giuliano, John, Guilliams, Kristin, Gaies, Michael, Gorga, Stephen, Hall, Mark, Hanson, Sheila, Hartman, Mary, Hassinger, Amanda, Irving, Sharon, Jeffries, Howard, Jouvet, Philippe, Kannan, Sujatha, Karam, Oliver, Khemani, Robinder, Kissoon, Niranjan, Lacroix, Jacques, Laussen, Peter, Leclerc, Francis, Lee, Jan, Leteurtre, Stephane, Lobner, Katie, McKiernan, Patrick, Menon, Kusum, Monagle, Paul, Muszynski, Jennifer, Odetola, Folafoluwa, Parker, Robert, Pathan, Nazima, Pierce, Richard, Pineda, Jose, Prince, Jose, Robinson, Karen, Rowan, Courtney, Ryerson, Lindsay, Sanchez-Pinto, L, Schlapbach, Luregn, Selewski, David, Shekerdemian, Lara, Simon, Dennis, Smith, Lincoln, Squires, James, Squires, Robert, Sutherland, Scott, Ouellette, Yves, Spaeder, Michael, Srinivasan, Vijay, Steiner, Marie, Tasker, Robert, Thiagarajan, Ravi, Thomas, Neal, Tissieres, Pierre, Traube, Chani, Tucci, Marisa, Typpo, Katri, Wainwright, Mark, Ward, Shan, Watson, R, Weiss, Scott, Whitney, Jane, Willson, Doug, Wynn, James, Yehya, Nadir, and Zimmerman, Jerry
- Abstract
Prior criteria for organ dysfunction in critically ill children were based mainly on expert opinion. We convened the Pediatric Organ Dysfunction Information Update Mandate (PODIUM) expert panel to summarize data characterizing single and multiple organ dysfunction and to derive contemporary criteria for pediatric organ dysfunction. The panel was composed of 88 members representing 47 institutions and 7 countries. We conducted systematic reviews of the literature to derive evidence-based criteria for single organ dysfunction for neurologic, cardiovascular, respiratory, gastrointestinal, acute liver, renal, hematologic, coagulation, endocrine, endothelial, and immune system dysfunction. We searched PubMed and Embase from January 1992 to January 2020. Study identification was accomplished using a combination of medical subject headings terms and keywords related to concepts of pediatric organ dysfunction. Electronic searches were performed by medical librarians. Studies were eligible for inclusion if the authors reported original data collected in critically ill children; evaluated performance characteristics of scoring tools or clinical assessments for organ dysfunction; and assessed a patient-centered, clinically meaningful outcome. Data were abstracted from each included study into an electronic data extraction form. Risk of bias was assessed using the Quality in Prognosis Studies tool. Consensus was achieved for a final set of 43 criteria for pediatric organ dysfunction through iterative voting and discussion. Although the PODIUM criteria for organ dysfunction were limited by available evidence and will require validation, they provide a contemporary foundation for researchers to identify and study single and multiple organ dysfunction in critically ill children.
- Published
- 2022
4. Coagulation in pediatric extracorporeal membrane oxygenation:A systematic review of studies shows lack of standardized reporting
- Author
-
Drop, Joppe, Van Den Helm, Suelyn, Monagle, Paul, Wildschut, Enno, de Hoog, Matthijs, Gunput, Sabrina T.G., Newall, Fiona, Dalton, Heidi J., MacLaren, Graeme, Ignjatovic, Vera, van Ommen, C. Heleen, Drop, Joppe, Van Den Helm, Suelyn, Monagle, Paul, Wildschut, Enno, de Hoog, Matthijs, Gunput, Sabrina T.G., Newall, Fiona, Dalton, Heidi J., MacLaren, Graeme, Ignjatovic, Vera, and van Ommen, C. Heleen
- Abstract
Objectives: Extracorporeal membrane oxygenation (ECMO) involves complex coagulation management and frequent hemostatic complications. ECMO practice between centers is variable. To compare results between coagulation studies, standardized definitions and clear documentation of ECMO practice is essential. We assessed how study population, outcome definitions, and ECMO-, coagulation-, and transfusion-related parameters were described in pediatric ECMO studies. Data sources: Embase, Medline, Web of Science, Cochrane Library and Google Scholar. Study selection: English original studies of pediatric ECMO patients describing hemostatic tests or outcome. Data extraction: Eligibility was assessed following PRISMA guidelines. Study population, outcome and ECMO-, coagulation, and transfusion parameters were summarized. Data synthesis: A total of 107 of 1312 records were included. Study population parameters most frequently included (gestational) age (79%), gender (60%), and (birth) weight (59%). Outcomes, including definitions of bleeding (29%), thrombosis (15%), and survival (43%), were described using various definitions. Description of pump type, oxygenator and cannulation mode occurred in 49%, 45%, and 36% of studies, respectively. The main coagulation test (53%), its reference ranges (49%), and frequency of testing (24%) were the most prevalent reported coagulation parameters. The transfusion thresholds for platelets, red blood cells, and fibrinogen were described in 27%, 18%, and 18% of studies, respectively. Conclusions: This systematic review demonstrates a widespread lack of detail or standardization of several parameters in coagulation research of pediatric ECMO patients. We suggest several parameters that might be included in future coagulation studies. We encourage the ECMO community to adopt and refine this list of parameters and to use standardized definitions in future research.
- Published
- 2022
5. Anticoagulation in pediatric cancer–associated venous thromboembolism:a subgroup analysis of EINSTEIN-Jr
- Author
-
Palumbo, Joseph S., Lensing, Anthonie W.A., Brandão, Leonardo R., Hooimeijer, Hélène L., Kenet, Gili, van Ommen, Heleen, Pap, Akos F., Majumder, Madhurima, Kubitza, Dagmar, Thelen, Kirstin, Willmann, Stefan, Prins, Martin H., Monagle, Paul, Male, Christoph, Palumbo, Joseph S., Lensing, Anthonie W.A., Brandão, Leonardo R., Hooimeijer, Hélène L., Kenet, Gili, van Ommen, Heleen, Pap, Akos F., Majumder, Madhurima, Kubitza, Dagmar, Thelen, Kirstin, Willmann, Stefan, Prins, Martin H., Monagle, Paul, and Male, Christoph
- Abstract
Anticoagulant treatment of pediatric cancer–associated venous thromboembolism (VTE) has not been prospectively evaluated. Management of anticoagulation for cancer-associated VTE is often challenged by drug interactions and treatment interruptions. A total of 56 of the 500 children (11.2%) with VTE who participated in the recent EINSTEIN-Jr randomized study had cancer (hematologic malignancy, 64.3%, solid malignant tumor, 35.7%). Children were allocated to either therapeutic-dose bodyweight-adjusted oral rivaroxaban (n=40) or standard anticoagulation with heparins, with or without vitamin K antagonists (n=16) and received a median of 30 concomitant medications. Based on sparse blood sampling at steady-state, pharmacokinetic (PK) parameters of rivaroxaban were derived using population PK modeling. During the 3 months of treatment, no recurrent VTE or major bleeding occurred (95% confidence interval, 0.0%-6.4%), and 3-month repeat imaging showed complete or partial vein recanalization in 20 and 24 of 52 evaluable children (38.5% and 46.2%, respectively). Anticoagulant treatment was interrupted 70 times in 26 (46.4%) children because of thrombocytopenia, invasive procedures, or adverse events, for a mean individual period of 5.8 days. Anticoagulant therapy was resumed in therapeutic doses and was not associated with thrombotic or bleeding complications. Rivaroxaban exposures were within the adult exposure range and similar to those observed in children with VTE who did not have cancer-associated VTE. Rivaroxaban and standard anticoagulants appeared safe and efficacious and were associated with reduced clot burden in most children with cancer-associated VTE, including those who had anticoagulant treatment interruptions. Rivaroxaban exposures were within the adult exposure range despite significant polypharmacy use.
- Published
- 2022
6. International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis
- Author
-
van Ommen, Heleen, Albisetti, M, Bhatt, M, Bonduel, M, Branchford, Brian, Chalmers, Elizabeth, Chan, A, Goldenberg, NA, Holzhauer, S, Monagle, Paul, Nowak-Gottl, U, Revel-Vilk, Shoshana, Sciuccatie, Gabriela, Sirachainan, Nongnuch, Male, Christoph, van Ommen, Heleen, Albisetti, M, Bhatt, M, Bonduel, M, Branchford, Brian, Chalmers, Elizabeth, Chan, A, Goldenberg, NA, Holzhauer, S, Monagle, Paul, Nowak-Gottl, U, Revel-Vilk, Shoshana, Sciuccatie, Gabriela, Sirachainan, Nongnuch, and Male, Christoph
- Abstract
Pediatric thromboembolism is a rare and heterogenous disease. As a result, there is a paucity of knowledge with regard to natural history, management, and outcomes of most types of pediatric venous and arterial thromboembolism. International research collaboration is needed to fill these knowledge gaps. Not only randomized controlled trials, but also representative observational studies are required to answer all research questions. Therefore, the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis initiated the International Pediatric Thrombosis Network (IPTN). The aims of the IPTN include (1) development of the Throm-PED registry to facilitate international prospective observational studies, and (2) establishment of a network of pediatric thrombosis centers experienced in effectively conducting clinical trials and observational studies. The IPTN needs dedicated clinicians all over the world and several funding sources to obtain high-quality research data to reach its ultimate goal of improving care in children with thrombosis. The aim of this communication is to call for active participation in the IPTN to all physicians taking care of children with thrombosis worldwide.
- Published
- 2021
7. Cross-sectional assessment of haemostatic profile and hepatic dysfunction in Fontan patients
- Author
-
Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, Daems, Joelle Julius Nicolaas, Attard, Chantal, Van Den Helm, Suelyn, Breur, Johannes, D'Udekem, Yves, Du Plessis, Karin, Wilson, Thomas G., Winlaw, David, Gentles, Thomas L., Monagle, Paul, Ignjatovic, Vera, Cardiologie onderzoek 1, Child Health, Circulatory Health, Regenerative Medicine and Stem Cells, Daems, Joelle Julius Nicolaas, Attard, Chantal, Van Den Helm, Suelyn, Breur, Johannes, D'Udekem, Yves, Du Plessis, Karin, Wilson, Thomas G., Winlaw, David, Gentles, Thomas L., Monagle, Paul, and Ignjatovic, Vera
- Published
- 2021
8. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).
- Author
-
UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Connor, Philip, Sánchez van Kammen, Mayte, Lensing, Anthonie W A, Chalmers, Elizabeth, Kállay, Krisztián, Hege, Kerry, Simioni, Paolo, Biss, Tina, Bajolle, Fanny, Bonnet, Damien, Grunt, Sebastian, Kumar, Riten, Lvova, Olga, Bhat, Rukhmi, Van Damme, An, Palumbo, Joseph, Santamaria, Amparo, Saracco, Paola, Payne, Jeanette, Baird, Susan, Godder, Kamar, Labarque, Veerle, Male, Christoph, Martinelli, Ida, Morales Soto, Michelle, Motwani, Jayashree, Shah, Sanjay, Hooimeijer, Helene L, Prins, Martin H, Kubitza, Dagmar, Smith, William T, Berkowitz, Scott D, Pap, Akos F, Majumder, Madhurima, Monagle, Paul, Coutinho, Jonathan M, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Connor, Philip, Sánchez van Kammen, Mayte, Lensing, Anthonie W A, Chalmers, Elizabeth, Kállay, Krisztián, Hege, Kerry, Simioni, Paolo, Biss, Tina, Bajolle, Fanny, Bonnet, Damien, Grunt, Sebastian, Kumar, Riten, Lvova, Olga, Bhat, Rukhmi, Van Damme, An, Palumbo, Joseph, Santamaria, Amparo, Saracco, Paola, Payne, Jeanette, Baird, Susan, Godder, Kamar, Labarque, Veerle, Male, Christoph, Martinelli, Ida, Morales Soto, Michelle, Motwani, Jayashree, Shah, Sanjay, Hooimeijer, Helene L, Prins, Martin H, Kubitza, Dagmar, Smith, William T, Berkowitz, Scott D, Pap, Akos F, Majumder, Madhurima, Monagle, Paul, and Coutinho, Jonathan M
- Abstract
Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebral venous thrombosis (CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued on heparin or switched to vitamin K antagonist). The main treatment period was 3 months. The primary efficacy outcome, symptomatic recurrent venous thromboembolism (VTE), and principal safety outcome, major or clinically relevant nonmajor bleeding,were centrally evaluated by blinded investigators. Sinus recanalization on repeat brain imaging was a secondary outcome. Statistical analyses were exploratory. In total, 114 children with confirmed CVT were randomized. All children completed the follow-up. None of the 73 rivaroxaban recipients and 1 (2.4%; CVT) of the 41 standard anticoagulant recipients had symptomatic, recurrent VTE after 3 months (absolute difference, 2.4%; 95% confidence interval [CI], -2.6% to 13.5%). Clinically relevant bleeding occurred in 5 (6.8%; all nonmajor and noncerebral) rivaroxaban recipients and in 1 (2.5%; major [subdural] bleeding) standard anticoagulant recipient (absolute difference, 4.4%; 95% CI, -6.7% to 13.4%). Complete or partial sinus recanalization occurred in 18 (25%) and 39 (53%) rivaroxaban recipients and in 6 (15%) and 24 (59%) standard anticoagulant recipients, respectively. In summary, in this substudy of a randomized trial with a limited sample size, children with CVT treated with rivaroxaban or standard anticoagulation had a low risk of recurrent VTE and clinically relevant bleeding. This trial was registered at clinicaltrials.gov as #NCT02234843.
- Published
- 2020
9. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
- Author
-
Haematologie patientenzorg, Haematologie, Child Health, Cluster B, Male, Christoph, Lensing, Anthonie W. A., Palumbo, Joseph S., Kumar, Riten, Nurmeev, Ildar, Hege, Kerry, Bonnet, Damien, Connor, Philip, Hooimeijer, Helene L., Torres, Marcela, Chan, Anthony K. C., Kenet, Gili, Holzhauer, Susanne, Santamaria, Amparo, Amedro, Pascal, Chalmers, Elizabeth, Simioni, Paolo, Bhat, Rukhmi V., Yee, Donald L., Lvova, Olga, Beyer-Westendorf, Jan, Biss, Tina T., Martinelli, Ida, Saracco, Paola, Peters, Marjolein, Kallay, Krisztian, Gauger, Cynthia A., Massicotte, M. Patricia, Young, Guy, Pap, Akos F., Majumder, Madhurima, Smith, William T., Heubach, Jurgen F., Berkowitz, Scott D., Thelen, Kirstin, Kubitza, Dagmar, Crowther, Mark, Prins, Martin H., Monagle, Paul, EINSTEIN-Jr Phase 3 Investigators, Haematologie patientenzorg, Haematologie, Child Health, Cluster B, Male, Christoph, Lensing, Anthonie W. A., Palumbo, Joseph S., Kumar, Riten, Nurmeev, Ildar, Hege, Kerry, Bonnet, Damien, Connor, Philip, Hooimeijer, Helene L., Torres, Marcela, Chan, Anthony K. C., Kenet, Gili, Holzhauer, Susanne, Santamaria, Amparo, Amedro, Pascal, Chalmers, Elizabeth, Simioni, Paolo, Bhat, Rukhmi V., Yee, Donald L., Lvova, Olga, Beyer-Westendorf, Jan, Biss, Tina T., Martinelli, Ida, Saracco, Paola, Peters, Marjolein, Kallay, Krisztian, Gauger, Cynthia A., Massicotte, M. Patricia, Young, Guy, Pap, Akos F., Majumder, Madhurima, Smith, William T., Heubach, Jurgen F., Berkowitz, Scott D., Thelen, Kirstin, Kubitza, Dagmar, Crowther, Mark, Prins, Martin H., Monagle, Paul, and EINSTEIN-Jr Phase 3 Investigators
- Published
- 2020
10. Dedicated paediatric teaching remains critical to the undergraduate medical curriculum
- Author
-
Pinnock, Ralph, Monagle, Paul, Couper, Jennifer, Wright, Ian M. R, Asher, Innes, Jones, Peter, Van Asperen, Peter, Mattes, Joerg, Pinnock, Ralph, Monagle, Paul, Couper, Jennifer, Wright, Ian M. R, Asher, Innes, Jones, Peter, Van Asperen, Peter, and Mattes, Joerg
- Abstract
Paediatrics, the branch of medicine responsible for the health and medical care of infants, children and adolescents from birth to young adulthood, is a relatively recent speciality with its origins in the mid-19th century.1 Unlike many other areas of practice, the population it serves is unable to advocate for itself. This often results in paediatrics being overlooked in planning services and education. One should note that a long protected childhood is unique to our species and essential for human mental and physical health.2 Dedicated paediatric teaching in the undergraduate/ postgraduate medical curriculum is essential, irrespective of the intended area of practice for the doctors in training. The reasons for this are as follows.
- Published
- 2014
11. Dedicated paediatric teaching remains critical to the undergraduate medical curriculum
- Author
-
Pinnock, Ralph, Monagle, Paul, Couper, Jennifer, Wright, Ian M. R, Asher, Innes, Jones, Peter, Van Asperen, Peter, Mattes, Joerg, Pinnock, Ralph, Monagle, Paul, Couper, Jennifer, Wright, Ian M. R, Asher, Innes, Jones, Peter, Van Asperen, Peter, and Mattes, Joerg
- Abstract
Paediatrics, the branch of medicine responsible for the health and medical care of infants, children and adolescents from birth to young adulthood, is a relatively recent speciality with its origins in the mid-19th century.1 Unlike many other areas of practice, the population it serves is unable to advocate for itself. This often results in paediatrics being overlooked in planning services and education. One should note that a long protected childhood is unique to our species and essential for human mental and physical health.2 Dedicated paediatric teaching in the undergraduate/ postgraduate medical curriculum is essential, irrespective of the intended area of practice for the doctors in training. The reasons for this are as follows.
- Published
- 2014
12. Reference ranges of coagulation tests
- Author
-
Monagle, Paul, Monagle, P ( Paul ), Speer, Oliver, Schmugge, Markus, Metzger, Claudia, Albisetti, Manuela, Monagle, Paul, Monagle, P ( Paul ), Speer, Oliver, Schmugge, Markus, Metzger, Claudia, and Albisetti, Manuela
- Abstract
Reference ranges are a set of values that correctly include most of the subjects with characteristics similar to the reference group and exclude the others. When accurate, reference ranges aid physicians to interpret results of clinical measurements and thus establish diagnosis. However, obtaining accurate reference ranges is a very demanding procedure. This chapter provides basic definitions and theories as well as a step-by-step procedure for the analysis of reference values and determination of reference ranges of coagulation, focusing on quantitative clinical laboratory assays. Preanalytical and analytical factors as well as dependence on the age influencing reference values for coagulation assays and their transference are discussed.
- Published
- 2013
13. Individually tailored client-focused reports for ubiquitous devices : an experimental analysis
- Author
-
Lamp, John, Smith, Stephen P., Lederman, Reeva, Monagle, Paul, Alzougool, Basil, Naish, Lee, Dreyfus, Suelette, Lamp, John, Smith, Stephen P., Lederman, Reeva, Monagle, Paul, Alzougool, Basil, Naish, Lee, and Dreyfus, Suelette
- Abstract
We describe results of a test of a method for tailoring communications based on the recipient’s preferred information processing style and dominant motivational attitude. Results indicate that the greater the match between the style of the report and the individual’s attributes, the more informed the reader feels about the subject of the report. This research has been conducted as part of a study into methods to design patient-centred medical using diabetic patients as an exemplar of chronic disease. The long term aim is to use reports personalised to the recipient to better inform patients about their disease and strengthen their motivation to follow the treatment plan.
- Published
- 2012
14. Age-Related Differences in Plasma Proteins: How Plasma Proteins Change from Neonates to Adults
- Author
-
Ignjatovic, Vera, Lai, Cera, Summerhayes, Robyn, Mathesius, Ulrike, Tawfilis, Sherif, Perugini, Matthew A., Monagle, Paul, Ignjatovic, Vera, Lai, Cera, Summerhayes, Robyn, Mathesius, Ulrike, Tawfilis, Sherif, Perugini, Matthew A., and Monagle, Paul
- Abstract
The incidence of major diseases such as cardiovascular disease, thrombosis and cancer increases with age and is the major cause of mortality world-wide, with neonates and children somehow protected from such diseases of ageing. We hypothesized that there are major developmental differences in plasma proteins and that these contribute to age-related changes in the incidence of major diseases. We evaluated the human plasma proteome in healthy neonates, children and adults using the 2D-DIGE approach. We demonstrate significant changes in number and abundance of up to 100 protein spots that have marked differences in during the transition of the plasma proteome from neonate and child through to adult. These proteins are known to be involved in numerous physiological processes such as iron transport and homeostasis, immune response, haemostasis and apoptosis, amongst others. Importantly, we determined that the proteins that are differentially expressed with age are not the same proteins that are differentially expressed with gender and that the degree of phosphorylation of plasma proteins also changes with age. Given the multi-functionality of these proteins in human physiology, understanding the differences in the plasma proteome in neonates and children compared to adults will make a major contribution to our understanding of developmental biology in humans.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.